PROMISE

Image

The initiative built on RESCEU (Respiratory Syncytial Virus Consortium in Europe), another IMI project which generated valuable insights into the impact of RSV on healthcare systems and society, amongst other significant results, such as creating a biorepository to assist future research. PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) brought together translational scientists, clinicians, public health agencies, the pharmaceutical industry, patient groups and clinical societies from 22 world class organisations to make a breakthrough in RSV (Respiratory Syncytial Virus) research. Funded by the Innovative Medicines Initiative (IMI), this initiative focused on advancing scientific knowledge on RSV to inform public health strategies and bolster the development and introduction of novel immunisations tools and therapeutics in Europe. Since the development of preventative measures such as a vaccine and monoclonal antibodies are well under way, PROMISE aims to prepare for the introduction of such treatments and prophylactic interventions.